原发性肠淋巴瘤研究进展
Research Advances in Primary Intestinal Lymphoma
DOI: 10.12677/acm.2025.153754, PDF,    科研立项经费支持
作者: 熊红丽, 尹 娅, 郑瑞燥, 柯腊梅, 邹宇骁, 俞慧宏*：重庆医科大学附属第二医院，消化内科，重庆
关键词: 原发性肠淋巴瘤；病因；诊断；治疗；Primary Intestinal Lymphoma； Etiology； Diagnosis； Treatment
摘要: 原发性肠淋巴瘤(primary intestinal lymphoma, PIL)是一种罕见且复杂的非霍奇金淋巴瘤，其发病率低，病理类型复杂，诊断困难，治疗方案尚未完善。近年来，现代影像技术显著提高了疾病的早期检出率和分期准确性，内镜检查结合实时活检技术增强了病理诊断的精确性，免疫组化和分子诊断手段的综合应用进一步提升了对亚型的鉴别能力，尽管化疗和放疗仍为标准治疗手段，但新型疗法如免疫治疗和靶向药物正在改写治疗格局。本文旨在深入探讨PIL的流行病学、病因学、临床特征、诊断标准、最佳治疗方案以及预后因素，以期为PIL患者的临床诊疗提供借鉴与参考。
Abstract: Primary intestinal lymphoma (PIL) is a rare and complex subtype of non-Hodgkin lymphoma, characterized by low incidence, diverse histopathology, diagnostic challenges, and lacking of standardized treatment protocols. Recent advancements in imaging, endoscopic techniques, and molecular diagnostics have significantly improved early detection and subtyping of PIL. Modern imaging modalities, such as CT and MRI, enhance disease identification and staging, while endoscopic techniques combined with real-time biopsy facilitate accurate pathological diagnosis. The integration of immunohistochemistry and molecular diagnostics further refines subtyping and provides valuable prognostic information. While chemotherapy and radiotherapy remain the main treatment for PIL, novel therapies, including immunotherapy and targeted agents, are increasingly contributing to improved outcomes. These advancements, alongside diagnostic innovations significantly alter the treatment landscape for patients with PIL. This review aims to provide a comprehensive overview of PIL, encompassing its epidemiology, etiology, clinical presentation, diagnostic criteria, optimal treatment strategies, and prognostic factors. By synthesizing current knowledge, this review seeks to offer valuable insights into the clinical management of patients with PIL, ultimately contributing to improving their diagnosis, treatment, and outcomes.
文章引用：熊红丽, 尹娅, 郑瑞燥, 柯腊梅, 邹宇骁, 俞慧宏. 原发性肠淋巴瘤研究进展[J]. 临床医学进展, 2025, 15(3): 1386-1396. https://doi.org/10.12677/acm.2025.153754

参考文献

[1] Bautista-Quach, M.A., Ake, C.D., Chen, M. and Wang, J. (2012) Gastrointestinal Lymphomas: Morphology, Immunophenotype and Molecular Features. Journal of Gastrointestinal Oncology, 3, 209-225.
[2] Kim, E.K., Jang, M., Yang, W.I. and Yoon, S.O. (2021) Primary Gastrointestinal T/NK Cell Lymphoma. Cancers, 13, Article No. 2679. [Google Scholar] [CrossRef] [PubMed]
[3] 李胜开, 袁晓丹, 代海洋, 刘国荣, 蓝博文. 原发性胃肠淋巴瘤临床、影像及病理对照研究[J]. 临床放射学杂志, 2020, 39(7): 1347-1350.
[4] Correa, M., Rout, P., Malipatel, R., Patil, M. and Devarbhavi, H. (2021) Primary Intestinal Lymphoma: Clinicopathological Characteristics of 55 Patients. Euroasian Journal of Hepato-Gastroenterology, 11, 71-75. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, Y., Chen, Y., Chen, S., Wu, L., Xu, L., Lian, G., et al. (2015) Primary Gastrointestinal Lymphoma: A Retrospective Multicenter Clinical Study of 415 Cases in Chinese Province of Guangdong and a Systematic Review Containing 5075 Chinese Patients. Medicine (Baltimore), 94, e2119. [Google Scholar] [CrossRef] [PubMed]
[6] Sedai, H., Shrestha, S., Chand, V., Poddar, E., Acharya, S. and Koirala, D. (2023) Diffuse Large B-Cell Lymphoma in a Patient Treated with Azathioprine for Ulcerative Colitis: A Case Report. Annals of Medicine & Surgery, 85, 2059-2063. [Google Scholar] [CrossRef] [PubMed]
[7] Russo, M.F., Diddoro, A., Iodice, A., Severi, C., Castagneto-Gissey, L. and Casella, G. (2023) Incidence of Lymphomas in Inflammatory Bowel Disease: Report of an Emblematic Case, Systematic Review, and Meta-Analysis. Frontiers in Medicine, 10, Article ID: 1172634. [Google Scholar] [CrossRef] [PubMed]
[8] Phillips, F., Verstockt, B., Ribaldone, D.G., Guerra, I., Teich, N., Katsanos, K., et al. (2021) Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series. Journal of Crohn’s and Colitis, 16, 500-505. [Google Scholar] [CrossRef] [PubMed]
[9] Pereira, M. (2014) Role of Helicobacter pylori in Gastric Mucosa-Associated Lymphoid Tissue Lymphomas. World Journal of Gastroenterology, 20, 684-698. [Google Scholar] [CrossRef] [PubMed]
[10] Vanagunas, A. (1997) Eradication of Helicobacter Pylori and Regression of B-Cell Lymphoma. Biomedicine & Pharmacotherapy, 51, 156-160. [Google Scholar] [CrossRef] [PubMed]
[11] Lecuit, M., Abachin, E., Martin, A., Poyart, C., Pochart, P., Suarez, F., et al. (2004) Immunoproliferative Small Intestinal Disease Associated with Campylobacter jejuni. New England Journal of Medicine, 350, 239-248. [Google Scholar] [CrossRef] [PubMed]
[12] Rodríguez-Sevilla, J.J. and Salar, A. (2021) Recent Advances in the Genetic of MALT Lymphomas. Cancers, 14, Article No. 176. [Google Scholar] [CrossRef] [PubMed]
[13] Nakamura, S., Matsumoto, T., Nakamura, S., Jo, Y., Fujisawa, K., Suekane, H., et al. (2003) Chromosomal Translocation T(11;18)(q21;q21) in Gastrointestinal Mucosa Associated Lymphoid Tissue Lymphoma. Journal of Clinical Pathology, 56, 36-42. [Google Scholar] [CrossRef] [PubMed]
[14] Fu, K., Weisenburger, D.D., Greiner, T.C., Dave, S., Wright, G., Rosenwald, A., et al. (2005) Cyclin D1-Negative Mantle Cell Lymphoma: A Clinicopathologic Study Based on Gene Expression Profiling. Blood, 106, 4315-4321. [Google Scholar] [CrossRef] [PubMed]
[15] Jang, J.H. and Lee, T. (2021) The Role of microRNAs in Cell Death Pathways. Yeungnam University Journal of Medicine, 38, 107-117. [Google Scholar] [CrossRef] [PubMed]
[16] Eis, P.S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M.F., et al. (2005) Accumulation of miR-155 and BIC RNA in Human B Cell Lymphomas. Proceedings of the National Academy of Sciences, 102, 3627-3632. [Google Scholar] [CrossRef] [PubMed]
[17] Kluiver, J., Poppema, S., de Jong, D., Blokzijl, T., Harms, G., Jacobs, S., et al. (2005) BIC and miR‐155 Are Highly Expressed in Hodgkin, Primary Mediastinal and Diffuse Large B Cell Lymphomas. The Journal of Pathology, 207, 243-249. [Google Scholar] [CrossRef] [PubMed]
[18] He, L., Thomson, J.M., Hemann, M.T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005) A microRNA Polycistron as a Potential Human Oncogene. Nature, 435, 828-833. [Google Scholar] [CrossRef] [PubMed]
[19] de Charette, M. and Houot, R. (2018) Hide or Defend, the Two Strategies of Lymphoma Immune Evasion: Potential Implications for Immunotherapy. Haematologica, 103, 1256-1268. [Google Scholar] [CrossRef] [PubMed]
[20] Velissari, A., Vassilakopoulos, T.P., Angelopoulou, M.K., Korkolopoulou, P., Bamias, G., Daikos, G., et al. (2022) Genetic Polymorphisms and Risk of MALT Lymphoma in Greek Population. Current Research in Translational Medicine, 70, Article ID: 103330. [Google Scholar] [CrossRef] [PubMed]
[21] Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., et al. (2015) Expression of Programmed Cell Death Ligand 1 Is Associated with Poor Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Blood, 126, 2193-2201. [Google Scholar] [CrossRef] [PubMed]
[22] Xing, W., Dresser, K., Zhang, R., Evens, A.M., Yu, H., Woda, B.A., et al. (2016) PD-L1 Expression in Ebv-Negative Diffuse Large B-Cell Lymphoma: Clinicopathologic Features and Prognostic Implications. Oncotarget, 7, 59976-59986. [Google Scholar] [CrossRef] [PubMed]
[23] Wojtukiewicz, M.Z., Rek, M.M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A.M., et al. (2021) Inhibitors of Immune Checkpoints—PD-1, PD-L1, Ctla-4—New Opportunities for Cancer Patients and a New Challenge for Internists and General Practitioners. Cancer and Metastasis Reviews, 40, 949-982. [Google Scholar] [CrossRef] [PubMed]
[24] Panneerselvam, K., Goyal, S. and Shirwaikar Thomas, A. (2020) Ileo-Colonic Lymphoma: Presentation, Diagnosis, and Management. Current Opinion in Gastroenterology, 37, 52-58. [Google Scholar] [CrossRef] [PubMed]
[25] Sharma, A., Raina, V., Vora, A., Shukla, N., Deo, S. and Dawar, R. (2006) Primary Gastrointestinal Non-Hodgkin’s Lymphoma Chemotherapy Alone an Effective Treatment Modality: Experience from a Single Centre in India. Indian Journal of Cancer, 43, 30-35. [Google Scholar] [CrossRef] [PubMed]
[26] Da, B., Zhang, J., Zhu, F., Wang, Z. and Diao, Y. (2024) Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Ileum in an Adult Presenting with Intussusception: A Case Report and Literature Review. Frontiers in Oncology, 14, Article ID: 1395144. [Google Scholar] [CrossRef] [PubMed]
[27] Zhao, R., Zhang, C., Zhang, Y., Sun, X., Ni, Y., Luo, Y., et al. (2019) Enteral Fistula as Initial Manifestation of Primary Intestinal Lymphoma. Chinese Medical Journal, 133, 101-102. [Google Scholar] [CrossRef] [PubMed]
[28] Chen, M., Liu, X., Zhang, Y. and Shi, Y. (2022) Endoscopic Features and Clinical Outcomes of Enteropathy-Associated T-Cell Lymphoma: A Tertiary Center Retrospective Study. Saudi Journal of Gastroenterology, 28, 127-134. [Google Scholar] [CrossRef] [PubMed]
[29] Dawson, I.M.P., Cornes, J.S. and Morson, B.C. (1961) Primary Malignant Lymphoid Tumours of the Intestinal Tract. Report of 37 Cases with a Study of Factors Influencing Prognosis. Journal of British Surgery, 49, 80-89. [Google Scholar] [CrossRef] [PubMed]
[30] 陈虹燕, 杨丽, 凌贤龙. 克罗恩病、肠结核及原发性肠道淋巴瘤的鉴别诊断研究进展[J]. 现代医药卫生, 2021, 37(3): 432-435.
[31] Erkut, M., Erkut, N., Bektas, O., Fidan, S., Cosar, A.M. and Sonmez, M. (2022) Effect of Clinical, Endoscopic, Radiological Findings, and Complications on Survival in Patients with Primary Gastrointestinal Lymphoma. The Turkish Journal of Gastroenterology, 33, 909-917. [Google Scholar] [CrossRef] [PubMed]
[32] 乔文礼, 赵晋华. 淋巴瘤18F-FDG PET_CT及PET_MR显像临床应用指南(2021版)解读与展望[J]. 中华核医学与分子影像杂志, 2022, 42(4): 193-195.
[33] Zhou, S., Chen, W., Lin, M., Chen, G., Chen, C., Huo, C., et al. (2021) Correlation of 18F-FDG PET/CT Suvmax with Clinical Features, D-Dimer and LDH in Patients with Primary Intestinal Lymphoma. Journal of International Medical Research, 49, 1-11. [Google Scholar] [CrossRef] [PubMed]
[34] 邵琳琳, 朱思莹, 邢洁, 武珊珊, 朱圣韬, 张澍田. 原发性胃肠道淋巴瘤的临床特征和内镜特点分析[J]. 首都医科大学学报, 2022, 43(2): 205-209.
[35] Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390. [Google Scholar] [CrossRef] [PubMed]
[36] Choi, W.W.L., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., et al. (2009) A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clinical Cancer Research, 15, 5494-5502. [Google Scholar] [CrossRef] [PubMed]
[37] Isaacson, P. and Wright, D.H. (1983) Malignant Lymphoma of Mucosa-Associated Lymphoid Tissue. A Distinctive Type of B-Cell Lymphoma. Cancer, 52, 1410-1416. [Google Scholar] [CrossRef] 
[38] Ishikawa, E., Nakamura, M., Satou, A., Shimada, K. and Nakamura, S. (2022) Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in the Gastrointestinal Tract in the Modern Era. Cancers, 14, Article No. 446. [Google Scholar] [CrossRef] [PubMed]
[39] Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. and Jaffe, E.S. (2011) The 2008 WHO Classification of Lymphoid Neoplasms and Beyond: Evolving Concepts and Practical Applications. Blood, 117, 5019-5032. [Google Scholar] [CrossRef] [PubMed]
[40] McCall, R.K., Pang, C.S. and Pettenati, M.J. (2020) Non-Nodal Cd5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion. Case Reports in Hematology, 2020, Article ID: 9185432. [Google Scholar] [CrossRef] [PubMed]
[41] Felten, C.L., Chan, J.A., DeCastro, D.R., Lopategui, J. and Rajurkar, S.P. (2018) Blastoid Variant Mantle Cell Lymphoma Expressing Aberrant CD3 and CD10 with Concurrent Small Lymphocytic Lymphoma: Establishment of a Clonal Relationship by B-and T-Cell Receptor Gene Rearrangements. Case Reports in Hematology, 2018, Article ID: 8303571. [Google Scholar] [CrossRef] [PubMed]
[42] 颜小杭, 张义. 原发性肠道淋巴瘤、克罗恩病及肠结核的CT影像诊断对比研究[J]. 中国医学前沿杂志(电子版), 2018, 10(1): 108-111.
[43] Rohatiner, A., d’Amore, F., Coiffier, B., Crowther, D., Gospodarowicz, M., Isaacson, P., et al. (1994) Report on a Workshop Convened to Discuss the Pathological and Staging Classifications of Gastrointestinal Tract Lymphoma. Annals of Oncology, 5, 397-400. [Google Scholar] [CrossRef] [PubMed]
[44] Reinartz, G., Molavi Tabrizi, C., Liersch, R., Ullerich, H., Hering, D., Willborn, K., et al. (2020) Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-Up of Two German Multicenter Consecutive Prospective Phase II Trials. The Oncologist, 25, e816-e832. [Google Scholar] [CrossRef] [PubMed]
[45] Katano, A., Takeuchi, K. and Yamashita, H. (2022) Radiotherapeutic Outcomes for Localized Primary Rectal Mucosa-Associated Lymphoid Tissue Lymphoma: A Consecutive Case Series of Three Patients. Cureus, 14, e22307. [Google Scholar] [CrossRef] [PubMed]
[46] Palma, G., Monti, S., Conson, M., Pacelli, R. and Cella, L. (2019) Normal Tissue Complication Probability (NTCP) Models for Modern Radiation Therapy. Seminars in Oncology, 46, 210-218. [Google Scholar] [CrossRef] [PubMed]
[47] Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., et al. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 34, 2232-2273. [Google Scholar] [CrossRef] [PubMed]
[48] Straining, R., Foss, F., Schiffer, M., Amin, K., Agarwal, S., Isufi, I., et al. (2025) Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 25, e96-e102. [Google Scholar] [CrossRef] [PubMed]
[49] Zinzani, P.L., Martelli, M., Magagnoli, M., Zaja, F., Storti, S., Pavone, E., et al. (1999) How Do Patients with Aggressive Non-Hodgkin’s Lymphoma Treated with Third-Generation Regimens (MACOP-B and F-MACHOP) Fare in the Long-Term? Haematologica, 84, 996-1001.
[50] Varga, Z., Bálint, A. and Vitályos, T. (2011) Surgical Interventions for Small Bowel Tumors at Our Department in the Last 3 Years. Magyar Sebészet, 64, 18-21. [Google Scholar] [CrossRef] [PubMed]
[51] Davis, B. and Rivadeneira, D.E. (2013) Complications of Colorectal Anastomoses: Leaks, Strictures, and Bleeding. Surgical Clinics of North America, 93, 61-87. [Google Scholar] [CrossRef] [PubMed]
[52] Iida, T., Nozawa, H., Sonoda, H., Toyama, K., Kawai, K., Hata, K., et al. (2020) Upfront Surgery for Small Intestinal Non-Hodgkin’s Lymphoma. Anticancer Research, 40, 2373-2377. [Google Scholar] [CrossRef] [PubMed]
[53] Karadag, M.A., Cecen, K., Demir, A., Bagcioglu, M., Kocaaslan, R. and Kadioglu, T.C. (2015) Gastrointestinal Complications of Laparoscopic/robot-Assisted Urologic Surgery and a Review of the Literature. Journal of Clinical Medicine Research, 7, 203-210. [Google Scholar] [CrossRef] [PubMed]
[54] Han, J., Zhu, Z., Zhang, C. and Xie, H. (2021) Successful Endoscopic Resection of Primary Rectal Mucosa-Associated Lymphoid Tissue Lymphoma by Endoscopic Submucosal Dissection: A Case Report. Frontiers in Medicine, 8, Article ID: 715256. [Google Scholar] [CrossRef] [PubMed]
[55] Kim, S.J., Choi, C.W., Mun, Y., Oh, S.Y., Kang, H.J., Lee, S.I., et al. (2011) Multicenter Retrospective Analysis of 581 Patients with Primary Intestinal Non-Hodgkin Lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer, 11, Article No. 321. [Google Scholar] [CrossRef] [PubMed]
[56] Lee, J., Kim, W.S., Kim, K., Ko, Y.H., Kim, J.J., Kim, Y.H., et al. (2004) Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. Leukemia & Lymphoma, 45, 339-344. [Google Scholar] [CrossRef] [PubMed]
[57] Shu, Y., Xu, X., Yang, W. and Xu, L. (2021) Surgery Plus Chemotherapy versus Chemotherapy Alone in Primary Intestinal Lymphoma: A Meta-analysis. Journal of International Medical Research, 49, 1-9. [Google Scholar] [CrossRef] [PubMed]
[58] d’Amore, F., Brincker, H., Grønbaek, K., Thorling, K., Pedersen, M., Jensen, M.K., et al. (1994) Non-Hodgkin’s Lymphoma of the Gastrointestinal Tract: A Population-Based Analysis of Incidence, Geographic Distribution, Clinicopathologic Presentation Features, and Prognosis. Danish Lymphoma Study Group. Journal of Clinical Oncology, 12, 1673-1684. [Google Scholar] [CrossRef] [PubMed]
[59] Wang, M., Ma, S., Shi, W., Zhang, Y., Luo, S. and Hu, Y. (2021) Surgery Shows Survival Benefit in Patients with Primary Intestinal Diffuse Large B‐Cell Lymphoma: A Population‐Based Study. Cancer Medicine, 10, 3474-3485. [Google Scholar] [CrossRef] [PubMed]
[60] Papageorgiou, S.G., Thomopoulos, T.P., Liaskas, A. and Vassilakopoulos, T.P. (2022) Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving Beyond Rituximab. Cancers, 14, Article No. 1917. [Google Scholar] [CrossRef] [PubMed]
[61] 张诗彤, 王爱民, 孙智慧, 宋晶晶, 玄小玉, 刘伟, 等. 利妥昔单抗联合CVAD方案对原发性胃肠道B细胞淋巴瘤患者血清VEGF、β2-MG水平的影响[J]. 海南医学院学报, 2019, 25(12): 901-904.
[62] Wen, T., Wang, J., Shi, Y., Qian, H. and Liu, P. (2020) Inhibitors Targeting Bruton’s Tyrosine Kinase in Cancers: Drug Development Advances. Leukemia, 35, 312-332. [Google Scholar] [CrossRef] [PubMed]
[63] Wen, Q., Gao, L., Xiong, J., Li, Q., Wang, S., Wang, J., et al. (2021) High-Dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation as Frontline Therapy for Intermediate/High-Risk Diffuse Large B Cell Lymphoma. Current Medical Science, 41, 465-473. [Google Scholar] [CrossRef] [PubMed]
[64] Noring, K., Carlsten, M., Sonnevi, K. and Wahlin, B.E. (2021) The Value of Complete Remission According to Positron Emission Tomography Prior to Autologous Stem Cell Transplantation in Lymphoma: A Population-Based Study Showing Improved Outcome. BMC Cancer, 21, Article No. 500. [Google Scholar] [CrossRef] [PubMed]
[65] Feng, M., Zhao, Z., Yang, M., Ji, J. and Zhu, D. (2021) T-Cell-Based Immunotherapy in Colorectal Cancer. Cancer Letters, 498, 201-209. [Google Scholar] [CrossRef] [PubMed]
[66] Li, C., Zhang, Y., Zhang, C., Chen, J., Lou, X., Chen, X., et al. (2019) Comparison of CART19 and Autologous Stem-Cell Transplantation for Refractory/Relapsed Non-Hodgkin’s Lymphoma. JCI Insight, 5, e130195.
[67] Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., et al. (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 380, 45-56. [Google Scholar] [CrossRef] [PubMed]
[68] Locke, F.L., Ghobadi, A., Jacobson, C.A., Miklos, D.B., Lekakis, L.J., Oluwole, O.O., et al. (2019) Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial. The Lancet Oncology, 20, 31-42. [Google Scholar] [CrossRef] [PubMed]
[69] Iwamuro, M., Tanaka, T., Ennishi, D., Matsueda, K., Yoshioka, M., Miyahara, K., et al. (2023) Long-Term Outcomes of Patients with Primary Intestinal Follicular Lymphoma Managed with Watch-and-Wait Strategy. Scientific Reports, 13, Article No. 5858. [Google Scholar] [CrossRef] [PubMed]
[70] Cha, R.R., Baek, D.H., Lee, G.W., Park, S.J., Lee, J.H., Park, J.H., et al. (2021) Clinical Features and Prognosis of Patients with Primary Intestinal B-Cell Lymphoma Treated with Chemotherapy with or without Surgery. The Korean Journal of Gastroenterology, 78, 320-327. [Google Scholar] [CrossRef] [PubMed]
[71] Delabie, J., Holte, H., Vose, J.M., Ullrich, F., Jaffe, E.S., Savage, K.J., et al. (2011) Enteropathy-Associated T-Cell Lymphoma: Clinical and Histological Findings from the International Peripheral T-Cell Lymphoma Project. Blood, 118, 148-155. [Google Scholar] [CrossRef] [PubMed]
[72] Read, J.A., Koff, J.L., Nastoupil, L.J., Williams, J.N., Cohen, J.B. and Flowers, C.R. (2014) Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. Clinical Lymphoma Myeloma and Leukemia, 14, 460-467.e2. [Google Scholar] [CrossRef] [PubMed]
[73] Fan, X., Zang, L., Zhao, B., Yi, H., Lu, H., Xu, P., et al. (2021) Development and Validation of Prognostic Scoring in Primary Intestinal Diffuse Large B-Cell Lymphoma: A Single-Institution Study of 184 Patients. Annals of Translational Medicine, 9, Article No. 1542. [Google Scholar] [CrossRef] [PubMed]
[74] Wang, K., Huang, X., Di Liberto, M. and Chen-Kiang, S. (2020) Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematology/Oncology Clinics of North America, 34, 809-823. [Google Scholar] [CrossRef] [PubMed]

为你推荐